CAS: 180384-56-9; N-(2-(2-(2H-Tetrazol-5-yl)Pyridin-4-yl)-6-(2-Hydroxyethoxy)-5-(2-Methoxyphenoxy)Pyrimidin-4-yl)-5-Methylpyridine-2-Sulfonamide
该化合物是一个复杂的有机化合物,其特点是其多功能结构,包括一个火利米丁核心,一个磺酰胺组,以及各种可增强其溶性和生物活动的替代成分.这种化合物具有四氮杂质特征,因其在药用化学,特别是在药物研制过程中的作用而闻名. 氢氧氧和甲基苯氧氧基组的存在有助于其作为生物活性剂的潜力,可能影响其与生物目标的相互作用. 磺酰胺组通常与抗菌特性有关,尽管该化合物的具体生物活动将取决于其分子层面的相互作用.
- 英文名称N-(2-(2-(2H-Tetrazol-5-yl)Pyridin-4-yl)-6-(2-Hydroxyethoxy)-5-(2-Methoxyphenoxy)Pyrimidin-4-yl)-5-Methylpyridine-2-Sulfonamide
- 中文名称克拉生坦
- IUPAC名称N-(2-(2-(2H-tetrazol-5-yl)pyridin-4-yl)-6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide
- CAS编号180384-56-9
- MFCD编号:MFCD20040418
- FDA UNII编号:3DRR0X4728
- 分子式:C25H23N9O6S分子量:577.58
- 产品CID: 929792
- 同类组份化合物CAS180384-56-9 (free)503271-02-1 (sodium)
- 产品分类有机原料 → 有机杂环化合物 → 二嗪类
物理性质
MSDS等安全信息
上下游产品
5-Methyl-Pyridine-2-Sulfonic Acid 6-Chloro-5-(2-Methoxy-Phenoxy)-2-(1-Oxy-Pyridin-4-yl)-Pyrimidin-4-Yl Amide 180385-42-6合成工艺路线路线简述
📜5-Methyl-Pyridine-2-Sulphonic Acid 2-(2-Cyano-Pyridin-4-yl)-6-(2-Hydroxy-Ethoxy)-5-(2-Methoxy-Phenoxy)-Pyrimidin-4-Yl-Amide置于sodium Azide,氯化铵,Sodium Nitrite,盐酸体系中,用 水,N,N-二甲基甲酰胺 用作溶剂,化学反应生成克拉生坦
参考文献:Wo2023/111299
标题:Wo2023/111299
海关参考信息
- 2905310000-1,2-乙二醇
2907210001-间苯二酚
2933310010-吡啶
2908199090-其他酚的卤化衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-6004965-A
优先权日:1994-12-20
标题 :Sulfonamides
发明人：BREU VOLKER; BURRI KASPAR; CASSAL JEAN-MARIE; CLOZEL MARTINE; HIRTH GEORGES; LOEFFLER BERND-MICHAEL; MUELLER MARCEL; NEIDHART WERNER; RAMUZ HENRI
权利人:HOFFMANN LA ROCHE
摘要:Compounds of the formula: ##STR1## where A, B, R 1 -R 8 are as described herein are endothelin inhibitors that can be used in treating diseases associated with endothelin, such as high blood pressure. Chemical synthesis of these compounds and pharmaceutical compositions containing these compounds are also useful.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Abunada S, Ashraf T, Kumar D, Moryani HA, Rai P, Abbasi S, Devi N, Turesh M, Dev S, Hyder S, Aizazuddin M, Kumar S, Kumar L, Khan S, Yusuf SA. Clazosentan for cerebral vasospasm prevention in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. BMC Neurol. 2025 Oct 6;25(1):413. doi: 10.1186/s12883-025-04429-5.
2: Jayaraj Ranjini N, Zahoor KA, Lakhani P, Suarez JI, Qureshi AI. Evaluating clazosentan sodium for the treatment of aneurysmal subarachnoid hemorrhage. Expert Rev Neurother. 2025 Dec;25(12):1385-1398. doi: 10.1080/14737175.2025.2564708. Epub 2025 Oct 2. 48(1):20. doi: 10.1007/s10143-024-03173-7.
126:173-181. doi: 10.1016/j.jocn.2024.06.019. Epub 2024 Jun 25. 93(6):1208-1219. doi: 10.1227/neu.0000000000002601. Epub 2023 Jul 18. 82(6):697-702. doi: 10.1007/s40265-022-01708-0.
合成参考文献
参考文献:10.1007/s12028-011-9583-y
摘要:Hänggi D; Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Monitoring and detection of vasospasm II: EEG and invasive monitoring. Neurocrit Care. 2011 Sep;15(2):318–23. doi: 10.1007/s12028-011-9583-y.
📝 需求与反馈
尽可能描述清楚需求与问题信息
